Hebatallah Ahmed Mohamed Moustafa1, Lamia Mohamed El Wakeel2, Mohamed Reda Halawa3, Nagwa Ali Sabri4, Alshaymaa Zaki El-Bahy5, Abdel Nasser Singab6. 1. Department of pharmacy practice, Faculty of Pharmacy and drug technology, Heliopolis University for Sustainable Development, Cairo Governorate, Egypt. 2. Department of Clinical Pharmacy, Faculty of pharmacy, Ain Shams University, Cairo Governorate, Egypt. lamywak@yahoo.com. 3. Department of Internal Medicine and Endocrinology, Faculty of Pharmacy, Ain Shams University, Cairo Governorate, Egypt. 4. Department of Clinical Pharmacy, Faculty of pharmacy, Ain Shams University, Cairo Governorate, Egypt. 5. Department of pharmacology & toxicology, faculty of pharmacy and drug technology, Heliopolis University for Sustainable Development, Cairo Governorate, Egypt. 6. Department of Pharmacognosy, Faculty of Pharmacy, Ain Shams University, Cairo Governorate, Egypt.
Abstract
PURPOSE: Nature is a phenomenal treasure of remedies. Numerous previous studies reported that Nigella sativa NS improved glycemic control, reduced insulin resistance, and improved lipid profile. NS was never investigated before as a monotherapy for newly diagnosed type 2 diabetes mellitus T2DM patients. Our aim was to investigate the potential metabolic benefits of NS monotherapy in newly diagnosed T2DM patients. METHOD: Prospective, open-label randomized clinical trial at outpatient endocrinology clinic at Ain-Shams University hospital. Eligible patients were randomly assigned to either metformin tablets or NS oil capsules. Both groups received treatment for 3 months. Glycemic index (FBG, 2 h pp, A1C, insulin sensitivity %S, secretory function %B, insulin resistance IR), lipid profile (TC, LDL, HDL, TG), liver and kidney functions (AST, ALT, Sr cr), total antioxidant capacityTAC, weight, waist circumference WC and body mass index BMI were assessed at baseline and at the end of treatment period. RESULTS: A concentration of 1350 mg/day NS in newly diagnosed T2DM patients was inferior to metformin in terms of lowering FBG, 2 h pp, and A1C or increasing %B. However, NS was comparable to metformin in lowering weight, WC, and BMI significantly. NS was comparable to metformin in regards of their effects on fasting insulin, %S, IR, ALT, TC, LDL, HDL, TG, and TAC. Metformin showed significant increase in AST and creatinine which was reserved in NS group. CONCLUSION: NS administration in newly diagnosed T2DM was tolerable with no side effects as compared to metformin; however, it was inferior to metformin in terms of diabetes management.
RCT Entities:
PURPOSE: Nature is a phenomenal treasure of remedies. Numerous previous studies reported that Nigella sativaNS improved glycemic control, reduced insulin resistance, and improved lipid profile. NS was never investigated before as a monotherapy for newly diagnosed type 2 diabetes mellitus T2DM patients. Our aim was to investigate the potential metabolic benefits of NS monotherapy in newly diagnosed T2DM patients. METHOD: Prospective, open-label randomized clinical trial at outpatient endocrinology clinic at Ain-Shams University hospital. Eligible patients were randomly assigned to either metformin tablets or NS oil capsules. Both groups received treatment for 3 months. Glycemic index (FBG, 2 h pp, A1C, insulin sensitivity %S, secretory function %B, insulin resistance IR), lipid profile (TC, LDL, HDL, TG), liver and kidney functions (AST, ALT, Sr cr), total antioxidant capacity TAC, weight, waist circumference WC and body mass index BMI were assessed at baseline and at the end of treatment period. RESULTS: A concentration of 1350 mg/day NS in newly diagnosed T2DM patients was inferior to metformin in terms of lowering FBG, 2 h pp, and A1C or increasing %B. However, NS was comparable to metformin in lowering weight, WC, and BMI significantly. NS was comparable to metformin in regards of their effects on fasting insulin, %S, IR, ALT, TC, LDL, HDL, TG, and TAC. Metformin showed significant increase in AST and creatinine which was reserved in NS group. CONCLUSION:NS administration in newly diagnosed T2DM was tolerable with no side effects as compared to metformin; however, it was inferior to metformin in terms of diabetes management.
Entities:
Keywords:
Metformin; Newly diagnosed type 2 diabetes mellitus; Nigella sativa
Authors: Bianca Hemmingsen; Søren S Lund; Christian Gluud; Allan Vaag; Thomas P Almdal; Christina Hemmingsen; Jørn Wetterslev Journal: Cochrane Database Syst Rev Date: 2013-11-11
Authors: A Benhaddou-Andaloussi; L C Martineau; D Vallerand; Y Haddad; A Afshar; A Settaf; P S Haddad Journal: Diabetes Obes Metab Date: 2009-09-25 Impact factor: 6.577
Authors: Kaushik Chattopadhyay; Haiquan Wang; Jaspreet Kaur; Gamze Nalbant; Abdullah Almaqhawi; Burak Kundakci; Jeemon Panniyammakal; Michael Heinrich; Sarah Anne Lewis; Sheila Margaret Greenfield; Nikhil Tandon; Tuhin Kanti Biswas; Sanjay Kinra; Jo Leonardi-Bee Journal: Front Pharmacol Date: 2022-06-08 Impact factor: 5.988
Authors: Angelika Sabine Sandholzer-Yilmaz; Eric Sven Kroeber; Wondimu Ayele; T Frese; Eva Johanna Kantelhardt; Susanne Unverzagt Journal: BMJ Open Date: 2022-05-11 Impact factor: 3.006
Authors: Erni Setiyorini; Mochammad Bagus Qomaruddin; Sony Wibisono; Titik Juwariah; Anggi Setyowati; Ning Arti Wulandari; Yeni Kartika Sari; Levi Tina Sari Journal: J Public Health Res Date: 2022-07-08